高盛-金域医学(603882.SS):竞争强度缓解,中国独立医学实验室龙头更强;上调至买入,目标价升至37元-KINGMED(603882.SS):China ICL leader emerges stronger as competition intensity eases;Upgrade to Buy,raise TP to Rmb37-20251217【12页】

发表回复

后才能评论